{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:12:19Z","timestamp":1773850339285,"version":"3.50.1"},"reference-count":45,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Soc. Bras. Med. Trop."],"DOI":"10.1590\/0037-8682-0565-2022","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T16:09:41Z","timestamp":1681488581000},"source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)"],"prefix":"10.1590","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4309-0304","authenticated-orcid":false,"given":"L\u00edvia Pimenta","family":"Bonif\u00e1cio","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5735-1333","authenticated-orcid":false,"given":"Eduardo","family":"Ramacciotti","sequence":"additional","affiliation":[{"name":"Science Valley Research Institute,  Brasil; Grupo Leforte,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9655-4734","authenticated-orcid":false,"given":"Leandro Barile","family":"Agati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8232-5375","authenticated-orcid":false,"given":"Fernando Crivelenti","family":"Vilar","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-4453","authenticated-orcid":false,"given":"Anna Christina Tojal da","family":"Silva","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2585-3870","authenticated-orcid":false,"given":"Paulo","family":"Louzada J\u00fanior","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3159-5687","authenticated-orcid":false,"given":"Benedito Ant\u00f4nio Lopes da","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7970-5403","authenticated-orcid":false,"given":"Hayala Cristina Cavenague de","family":"Souza","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3588-3370","authenticated-orcid":false,"given":"Caroline Candida Carvalho de","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Science Valley Research Institute,  Brasil; Grupo Leforte,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9950-0415","authenticated-orcid":false,"given":"Val\u00e9ria Cristina Resende","family":"Aguiar","sequence":"additional","affiliation":[{"name":"Science Valley Research Institute,  Brasil; Grupo Leforte,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2098-0706","authenticated-orcid":false,"given":"Carlos Augusto de Aguiar","family":"Quadros","sequence":"additional","affiliation":[{"name":"Grupo Leforte,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6243-8855","authenticated-orcid":false,"given":"Cesar","family":"Dusilek","sequence":"additional","affiliation":[{"name":"Hospital do Rocio,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9708-0294","authenticated-orcid":false,"given":"Kengi","family":"Itinose","sequence":"additional","affiliation":[{"name":"Hospital do Rocio,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5583-6408","authenticated-orcid":false,"given":"Ricardo","family":"Risson","sequence":"additional","affiliation":[{"name":"Hospital do Rocio,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6049-7503","authenticated-orcid":false,"given":"Lucas Roberto Rivabem","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Hospital do Rocio,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-4961","authenticated-orcid":false,"given":"Renato Delascio","family":"Lopes","sequence":"additional","affiliation":[{"name":"Brazilian Clinical Research Institute,  Brasil; Duke University Medical Center,  USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2026-6925","authenticated-orcid":false,"given":"Esper Georges","family":"Kallas","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3736-7127","authenticated-orcid":false,"given":"Fernando","family":"Bellissimo-Rodrigues","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2023]]},"reference":[{"key":"ref1","series-title":"COVID-19 Clinical management: living guidance","year":"2022"},{"issue":"23","key":"ref2","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"Fajgenbaum DC","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"ref3","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.2174\/0929867328666201209100259","article-title":"The Role of Interleukin-6 in the Pathogenesis, Prognosis and Treatment of Severe COVID-19","volume":"28","author":"Giannakodimos I","year":"2021","journal-title":"Curr Med Chem"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/path.5642","article-title":"COVID-19: immunopathology, pathophysiological mechanisms, and treatment options","volume":"254","author":"van Eijk LE","year":"2021","journal-title":"J Pathol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"11772719221106600","DOI":"10.1177\/11772719221106600","article-title":"Elevated Levels of Pleiotropic Interleukin-6 (IL-6) and Interleukin-10 (IL-10) are Critically Involved With the Severity and Mortality of COVID-19: An Updated Longitudinal Meta-Analysis and Systematic Review on 147 Studies","volume":"17","author":"Jafrin S","year":"2022","journal-title":"Biomark Insights"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano T","year":"2021","journal-title":"Int Immunol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"789735","DOI":"10.3389\/fimmu.2021.789735","article-title":"Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients","volume":"12","author":"Caldrer S","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273186","article-title":"Excessive neutrophil recruitment promotes typical T-helper 17 responses in Coronavirus disease 2019 patients","volume":"17","author":"Choto TA","year":"2022","journal-title":"PloS One"},{"key":"ref9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","author":"Mills KHG","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13131","article-title":"COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges","volume":"95","author":"Pourgholaminejad A","year":"2022","journal-title":"Scand J Immunol"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1002\/jcp.30047","article-title":"Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls","volume":"236","author":"Sadeghi A","year":"2021","journal-title":"J Cell Physiol"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski R","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"626235","DOI":"10.3389\/fimmu.2021.626235","article-title":"High Levels of Circulating IL-8 and Soluble IL-2R Are Associated With Prolonged Illness in Patients With Severe COVID-19","volume":"12","author":"Ma A","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41423-020-0484-x","article-title":"Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients","volume":"17","author":"Zhang Y","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"ref15","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.4049\/jimmunol.1000142","article-title":"IL-17 enhancement of the IL-6 signaling cascade in astrocytes","volume":"184","author":"Ma X","year":"2010","journal-title":"J Immunol"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ni1439","article-title":"The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease","volume":"8","author":"Qian Y","year":"2007","journal-title":"Nat Immunol"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"102293","DOI":"10.1016\/j.isci.2021.102293","article-title":"ORF8 contributes to cytokine storm during SARS-CoV-2 infection by activating IL-17 pathway","volume":"24","author":"Lin X","year":"2021","journal-title":"iScience"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"L6","DOI":"10.1152\/ajplung.00344.2017","article-title":"IL-17 in the lung: the good, the bad, and the ugly","volume":"314","author":"Gurczynski SJ","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120912","article-title":"High peripheral blood th17 percent associated with poor lung function in cystic fibrosis","volume":"10","author":"Mulcahy EM","year":"2015","journal-title":"PloS One"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.4049\/jimmunol.1100917","article-title":"IL-17 boosts proinflammatory outcome of antiviral response in human cells","volume":"187","author":"Ryzhakov G","year":"2011","journal-title":"J Immunol"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/bcp.14437","article-title":"Potential role of IL-17 blocking agents in the treatment of severe COVID-19?","volume":"87","author":"Bulat V","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu L","year":"2016","journal-title":"J Inflamm Res"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S2213-2600(21)00435-5","article-title":"Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"9","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"13","key":"ref24","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial","volume":"324","author":"Angus DC","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242318","article-title":"Colchicine reduces lung injury in experimental acute respiratory distress syndrome","volume":"15","author":"Dupuis J","year":"2020","journal-title":"PloS One"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001455","article-title":"Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial","volume":"7","author":"Lopes MI","year":"2021","journal-title":"RMD Open"},{"issue":"6979","key":"ref27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature02393","article-title":"Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain","volume":"428","author":"Ravelli RB","year":"2004","journal-title":"Nature"},{"issue":"8","key":"ref28","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2213-2600(21)00222-8","article-title":"Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial","volume":"9","author":"Tardif JC","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1084\/jem.20160417","article-title":"IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21-producing B helper CD8+ T cells","volume":"213","author":"Yang R","year":"2016","journal-title":"J Exp Med"},{"issue":"6","key":"ref30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13136","article-title":"Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial","volume":"3","author":"Deftereos SG","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"12","key":"ref31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.41328","article-title":"Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial","volume":"4","author":"Diaz R","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11606-021-07203-8","article-title":"Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID)","volume":"37","author":"Absalon-Aguilar A","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.18087\/cardio.2021.2.n1560","article-title":"Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study","volume":"61","author":"Mareev VY","year":"2021","journal-title":"Kardiologiia"},{"key":"ref34","series-title":"R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis","year":"2020"},{"key":"ref35","series-title":"R: A language and environment for statistical computing. R Foundation for Statistical Computing","year":"2021"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.2147\/IJGM.S329810","article-title":"Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID)","volume":"14","author":"Pascual-Figal DA","year":"2021","journal-title":"Int J Gen Med"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ptr.7319","article-title":"Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial","volume":"36","author":"Pourdowlat G","year":"2022","journal-title":"Phytother Res: PTR"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1038\/s41598-022-13424-6","article-title":"Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trial","volume":"12","author":"Cecconi A","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1684\/ecn.2021.0463","article-title":"Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19)","volume":"32","author":"Maslennikov R","year":"2021","journal-title":"Eur Cytokine Netw"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"155627","DOI":"10.1016\/j.cyto.2021.155627","article-title":"Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study","volume":"146","author":"Avdeev SN","year":"2021","journal-title":"Cytokine"},{"issue":"8","key":"ref41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/23744235.2022.2066171","article-title":"Blockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients - the BISHOP study","volume":"54","author":"Resende GG","year":"2022","journal-title":"Infect Dis"},{"issue":"8","key":"ref42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41584-019-0243-5","article-title":"Systemic effects of IL-17 in inflammatory arthritis","volume":"15","author":"Beringer A","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"ref43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273340","article-title":"Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study","volume":"17","author":"Bryushkova EA","year":"2022","journal-title":"PloS One"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3892\/etm.2021.9658","article-title":"Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19","volume":"21","author":"Zhu ME","year":"2021","journal-title":"Exp Ther Med"},{"issue":"10339","key":"ref45","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses","volume":"399","year":"2022","journal-title":"Lancet"}],"container-title":["Revista da Sociedade Brasileira de Medicina Tropical"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0037-86822023000100317&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T16:10:01Z","timestamp":1681488601000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0037-86822023000100317&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":45,"alternative-id":["S0037-86822023000100317"],"URL":"https:\/\/doi.org\/10.1590\/0037-8682-0565-2022","relation":{},"ISSN":["1678-9849","0037-8682"],"issn-type":[{"value":"1678-9849","type":"electronic"},{"value":"0037-8682","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"e0565-2022"}}